Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008-present). (Q38018637)

27 August 2017

Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008-present). (English)

1 reference

Manfred Schubert-Zsilavecz

27 August 2017

Christina Lamers

1

0 references

Daniel Merk

object named as

Daniel Merk

series ordinal

3

0 references

series ordinal

2

object named as

Manfred Schubert-Zsilavecz

1 reference

PubMed ID

22697317

27 August 2017

language of work or name

English

0 references

publication date

15 June 2012

1 reference

Expert Opinion on Therapeutic Patents

27 August 2017

1 reference

27 August 2017

22

1 reference

27 August 2017

803-841

1 reference

27 August 2017

7

1 reference

Nuclear receptors as pharmaceutical targets: rise of FXR and rebirth of PPAR?

27 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.699042

Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.699042

The mechanisms of action of PPARs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.699042

Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.699042

Thematic review series: skin lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.699042

New insights into the role of peroxisome proliferator-activated receptors in regulating the inflammatory response after tissue injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.699042

Principles for modulation of the nuclear receptor superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.699042

Discovery of a novel class of 2-mercaptohexanoic acid derivatives as highly active PPARalpha agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.699042

Structural basis for the design of PPAR-gamma ligands: a survey on quantitative structure- activity relationships.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.699042

Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.699042

Design, synthesis, and structure-activity relationship study of peroxisome proliferator-activated receptor (PPAR) delta-selective ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.699042

PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.699042

PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.699042

PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.699042

PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.699042

Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.699042

Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.699042

Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.699042

Identification and characterization of a selective peroxisome proliferator-activated receptor beta/delta (NR1C2) antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.699042

10.1517/13543776.2012.699042

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

22697317